Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide vs Insulin Glargine in T2D (AWARD-2)
NCT01075282Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2010
- Primary completion
- May 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 20
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Feb 2010; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01075282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01075282.